Tyra Biosciences, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: TYRA · Form: DEF 14A · Filed: Apr 18, 2024 · CIK: 1863127
| Field | Detail |
|---|---|
| Company | Tyra Biosciences, Inc. (TYRA) |
| Form Type | DEF 14A |
| Filed Date | Apr 18, 2024 |
| Risk Level | |
| Pages | 16 |
| Reading Time | 20 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: Tyra Biosciences, Annual Meeting, Proxy Statement, Virtual Meeting, Stockholders
TL;DR
<b>Tyra Biosciences, Inc. will host its 2024 Annual Meeting of Stockholders virtually on May 29, 2024, with proxy materials available online.</b>
AI Summary
Tyra Biosciences, Inc. (TYRA) filed a Proxy Statement (DEF 14A) with the SEC on April 18, 2024. Tyra Biosciences, Inc. will hold its 2024 Annual Meeting of Stockholders on May 29, 2024, at 10:00 a.m. Pacific Time. The meeting will be conducted virtually via live webcast. The company is utilizing rules allowing for internet distribution of proxy materials to reduce costs and environmental impact. Stockholders will receive a notice with instructions to access proxy materials online and vote. Printed or email copies of proxy materials can be requested by following instructions in the Notice of Internet Availability.
Why It Matters
For investors and stakeholders tracking Tyra Biosciences, Inc., this filing contains several important signals. The virtual meeting format and internet distribution of proxy materials aim to reduce operational costs and environmental impact for the company. This approach allows stockholders to access information and vote conveniently while enabling the company to streamline the proxy process.
Risk Assessment
Risk Level: — Tyra Biosciences, Inc. shows moderate risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks disclosed.
Analyst Insight
Stockholders should review the proxy materials to understand the proposals and vote their shares for the upcoming annual meeting.
Key Numbers
- May 29, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
- 10:00 a.m. Pacific Time — Annual Meeting Time (2024 Annual Meeting of Stockholders)
Key Players & Entities
- Tyra Biosciences, Inc. (company) — Registrant name
- May 29, 2024 (date) — Date of Annual Meeting
- 2024 (date) — Year of Annual Meeting
- April 18, 2024 (date) — Date of filing
- 2656 State Street Carlsbad, CA 92008 (address) — Company business address
FAQ
When did Tyra Biosciences, Inc. file this DEF 14A?
Tyra Biosciences, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 18, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Tyra Biosciences, Inc. (TYRA).
Where can I read the original DEF 14A filing from Tyra Biosciences, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Tyra Biosciences, Inc..
What are the key takeaways from Tyra Biosciences, Inc.'s DEF 14A?
Tyra Biosciences, Inc. filed this DEF 14A on April 18, 2024. Key takeaways: Tyra Biosciences, Inc. will hold its 2024 Annual Meeting of Stockholders on May 29, 2024, at 10:00 a.m. Pacific Time.. The meeting will be conducted virtually via live webcast.. The company is utilizing rules allowing for internet distribution of proxy materials to reduce costs and environmental impact..
Is Tyra Biosciences, Inc. a risky investment based on this filing?
Based on this DEF 14A, Tyra Biosciences, Inc. presents a moderate-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks disclosed.
What should investors do after reading Tyra Biosciences, Inc.'s DEF 14A?
Stockholders should review the proxy materials to understand the proposals and vote their shares for the upcoming annual meeting. The overall sentiment from this filing is neutral.
How does Tyra Biosciences, Inc. compare to its industry peers?
Tyra Biosciences, Inc. is a biotechnology company operating in the pharmaceutical preparations sector.
Are there regulatory concerns for Tyra Biosciences, Inc.?
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.
Industry Context
Tyra Biosciences, Inc. is a biotechnology company operating in the pharmaceutical preparations sector.
Regulatory Implications
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.
What Investors Should Do
- Review the proxy statement for details on proposals to be voted on at the Annual Meeting.
- Vote your shares by phone, internet, or mail as instructed in the Notice of Internet Availability.
- Request printed or email copies of proxy materials if preferred over online access.
Key Dates
- 2024-05-29: Annual Meeting of Stockholders — Key date for stockholder voting and participation.
- 2024-04-18: Filing Date — Date the proxy statement was filed with the SEC.
Year-Over-Year Comparison
This is a DEF 14A filing for the 2024 Annual Meeting, following standard proxy statement procedures.
Filing Stats: 4,925 words · 20 min read · ~16 pages · Grade level 12.3 · Accepted 2024-04-18 16:02:28
Key Financial Figures
- $0.0001 — f record of shares of our common stock, $0.0001 par value per share (Common Stock), as
Filing Documents
- d752944ddef14a.htm (DEF 14A) — 410KB
- g752944dsp2a.jpg (GRAPHIC) — 1KB
- g752944g41o23.jpg (GRAPHIC) — 24KB
- g752944g56o91.jpg (GRAPHIC) — 35KB
- g752944img1.jpg (GRAPHIC) — 3KB
- g752944img2.jpg (GRAPHIC) — 29KB
- g752944img3.jpg (GRAPHIC) — 2KB
- g752944img4.jpg (GRAPHIC) — 1KB
- g752944img5.jpg (GRAPHIC) — 1KB
- g752944img6.jpg (GRAPHIC) — 2KB
- g752944img7.jpg (GRAPHIC) — 1KB
- g752944img8.jpg (GRAPHIC) — 6KB
- 0001193125-24-100755.txt ( ) — 553KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 33 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 36 2025 STOCKHOLDER PROPOSALS 38 TYRAS ANNUAL REPORT ON FORM 10-K 40 Table of Contents PROXY STATEMENT TYRA BIOSCIENCES, INC. 2656 State Street, Carlsbad, California 92008 General This proxy statement is furnished in connection with the solicitation by the board of directors (the Board) of Tyra Biosciences, Inc. of proxies to be voted at our Annual Meeting of Stockholders to be held virtually on Wednesday, May 29, 2024 (the Annual Meeting), at 10:00 a.m., Pacific Time, and at any continuation, postponement or adjournment thereof. Holders of record of shares of our common stock, $0.0001 par value per share (Common Stock), as of the close of business on April 4, 2024 (the Record Date), will be entitled to notice of and to vote at the Annual Meeting and any continuation, postponement or adjournment thereof. As of the Record Date, there were 52,523,850 shares of our Common Stock outstanding and entitled to vote at the Annual Meeting. Each share of Common Stock is entitled to one vote on any matter presented to stockholders at the Annual Meeting. This proxy statement and the Companys Annual Report to Stockholders for the year ended December 31, 2023 (the 2023 Annual Report), or Notice of Internet Availability of Proxy Materials, as applicable, will be sent on or about April 18, 2024 to our stockholders on the Record Date. In this proxy statement, Tyra, the Company, we, us and our refer to Tyra Biosciences, Inc. IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON WEDNESDAY, MAY 29, 2024: This Proxy Statement and our 2023 Annual Report to Stockholders are available at: www.proxydocs.com/TYRA. Proposals At the Annual Meeting, our stockholders will be asked: 1. To elect Melissa McCracken, Ph.D., Jake Simson, Ph.D. and Rehan Verjee as Class III directors for a th